SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending as its community rallies around recent developments, including a new listing and upcoming mobile app. Active community members emphasize their dedication and 'grind,' expressing excitement for the project's future and potential for significant growth. The coin is being viewed as undervalued, with community members noting its presence on major platforms and encouraging others to DYOR.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas is surging as the community discusses potential government investment in the company's Thacker Pass project, driven by interest in securing domestic lithium sources.  The community's focus is on whether the stock can sustain its momentum, with some anticipating a short squeeze while others expect a pullback.  This spike occurs amidst broader discussions about government involvement in critical mineral supply chains.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid heated discussions surrounding political rhetoric and its potential consequences, particularly in the wake of recent events. Community members are actively debating freedom of speech, censorship, and the role of political figures in inciting violence. The stock's movement is also being discussed in relation to broader political and economic themes.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as the community discusses potential ticker suppression on Stocktwits and an unusual ticker behavior right before earnings. Investors speculate about possible manipulation and whether the earnings report will trigger a significant price movement. Many express strong bullish sentiment, anticipating a squeeze and highlighting partnerships and the potential of QNX technology.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

SQD.X is experiencing heightened interest, with community members noting significant buying pressure and anticipating a potential parabolic move. Others express concerns about a lack of support and potential for a crash, leading to a divided sentiment as traders weigh the possibilities of a big move. The coin's volatility is also being actively discussed.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

IMRX is trending following positive Phase 2a trial data for its pancreatic cancer treatment, showing promising survival rates. Despite the encouraging news, the stock experienced a significant drop, leading to discussions about potential dilution and market manipulation. The community is weighing the long-term potential against short-term risks, with some expressing frustration and others remaining optimistic about future gains.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is surging due to promising clinical trial data for its Huntington's disease gene therapy, showing a significant slowing of disease progression and potential FDA approval, with analysts increasing price targets. Community members are weighing the potential for long-term gains against concerns about upcoming dilution from a public offering and insider selling. The stock is experiencing high volatility as traders debate a potential short squeeze amid positive momentum in the biotech sector.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is trending amid unconfirmed speculation of a potential takeover, with community members pointing to unusual trading volume and analyst reports as possible supporting evidence. The potential buyer is rumored to be a strategic player seeking a bridge loan for the acquisition. Community discussions also involve short interest, the upcoming EMA approval, and potential buyout price.

Fusion Fuel Green Plc engages in the research and development of solar technologies. It develops a process and technology to produce emission-free green hydrogen using concentrated photovoltaic technology. The company was founded in 2018 and is headquartered in Dublin, Ireland.

Fusion Fuel Green Ltd - Ordinary Shares - Class A

Fusion Fuel Green PLC

HTOO is trending due to a recently announced non-binding term sheet for hydrogen infrastructure investments, sparking discussions about its potential despite past performance concerns. While some view the news as a catalyst for growth given the low float, others remain skeptical, pointing to the non-binding nature of the agreement and potential dilution. Community members are actively debating the stock's prospects and whether it can sustain its gains.

🚀 ASTER INU – Where memes meet the multichain future 🌌  ASTER INU isn’t just another meme coin—it’s the cosmic pupper on a mission! Inspired by Aster’s dream of seamless cross-chain connectivity, this Inu blends serious crypto utility with the chaotic joy of meme culture.  Think of it as: ✨ The wagmi energy of DOGE 🌐 The connectivity of Aster 😂 The meme magic of the internet  We’re building a community-first galaxy, where holders are not just investors—they’re explorers, jokers, and culture shapers. Whether you’re here for the memes, the vibes, or the vision of a chain-connected future, ASTER INU has a seat for you on this rocketship. 🚀🐶

Aster INU

Aster INU ($ASTERINU.X) is trending amid community discussion around recent price movement. Social media conversations suggest increased interest in the cryptocurrency, with some users speculating on potential gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Neuphoria Therapeutics Inc. soared more than 11% in premarket trading on Wednesday, propelling the micro-cap biotech stock into the top 10 trending symbols on Stocktwits.&nbsp;The company is set to receive a $15 million milestone payment from Merck, triggered by the latter's initiation of a Phase 2 clinical trial to assess the safety and efficacy of MK-1167, an experimental drug for Alzheimer's disease dementia.&nbsp;This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments, along with royalties on any licensed medicines.Investors on the platform have expressed enthusiasm, with one user speculating that the stock could reach double digits soon, while another suggested it should ideally trade at more than triple its current levels.<stembedurl>https://stocktwits.com/Tigerphoenix/message/603914417</stembedurl><stembedurl>https://stocktwits.com/Realtrader77/message/603914418</stembedurl>Neuphoria, which has a market cap of just over $7.2 million, saw an 86% jump in following over the past month and a 1,200% increase in message volume on Stocktwits in the last week.&nbsp;Earlier in the month, H.C. Wainwright raised its price target on Neuphoria to $21 from $8, maintaining a 'Buy' rating.&nbsp;The research firm said its valuation argument was based on the company's progress with its broad-spectrum anti-anxiety therapeutic, BNC210.&nbsp;According to Koyfin data, at the end of the September quarter, Neuphoria had approximately $8 million in cash and investments and total debt under $220,000.&nbsp;<a href="https://stocktwits.com/symbol/NEUP">Neuphoria's stock</a> has lost more than 63% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes

This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.

Equity

This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.


Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Stocktwits

Costco Wholesale Corp

) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

NEUP
Neuphoria Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest NEUP News

NEUP Neuphoria Therapeutics Inc.